Novo Nordisk

Novo Nordisk




Global healthcare specialist, Novo Nordisk is a leader in innovation and a world leader in diabetes care for 88 years. The Company also holds a leading position in the areas of treatment of hemophilia, treatment with growth hormone and hormone replacement therapy. Based in Denmark, Novo Nordisk employs more than 32,000 people in 75 countries and markets its products in 179 countries. Its common shares are listed on NASDAQ OMX Copenhagen (Novo-B) and its American Depositary Receipts (ADRs) are listed on the New York Stock Exchange (NVO).
The industrial partnership concluded on April 21st, 2012 intend the production of insulin in the range Novo Nordisk in Constantine (Algeria).
This strategic partnership has two major components. The first stage, intend to produce locally human insulin in conventional form. The second stage aims at the establishment of a local production of all insulin Novo Nordisk in Algeria.

The first stage of this partnership is to upgrade the conventional insulin production facilities of the factory Saidal Group in Constantine through the establishment of a leading quality system (Management system QMS Quality) in accordance with the European GMP Good manufacturing Practices. This is associated with the training of staff and a Novo Nordisk technology transfer to Saidal Group. This stage is underway.

A weekly supervision is provided by Novo Nordisk experts to ensure the success of the project on time.

The second stage for the production of the entire range of Novo Nordisk insulin through the creation of a new plant (Greenfield project) also located in Constantine.

This partnership with high added value is based on a transfer of technology and significant skills Novo Nordisk, a world leader in diabetes care, to Saidal Group. The quality standards of this plant are identical to those plants Novo Nordisk around the world.